ClinicalTrials.gg
CompletedNCT05521191Updated Jun 3, 2025

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

A Phase 1 interventional study of RGLS8429 and Placebo in Autosomal Dominant Polycystic Kidney Disease, ADPKD and Polycystic Kidney, Autosomal Dominant, sponsored by Regulus Therapeutics Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Regulus Therapeutics Inc. (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
27th of 63
68 · median 48
Started
2022
with 5 others
Phase 1
10 of 85
2 open now
Registered
68th of 85
by date
Lead sponsor
3 of 85
Regulus Therapeutics Inc.

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 27th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2022, is one of 10 in phase 1, and was the 68th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

Primary Objectives

  • To assess the safety and tolerability of RGLS8429
  • To assess the impact of RGLS8429 on ADPKD biomarkers

Secondary Objectives

  • To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)
  • To characterize the pharmacokinetic (PK) properties of RGLS8429
  • To assess the impact of RGLS8429 on renal function
Read the detailed description

This is a randomized, double-blind, placebo-controlled multiple ascending dose and an open-label fixed-dose Phase 1b study consisting of two parts, Part A and Part B. In Part A, multiple ascending doses of RGLS8429 or placebo will be administered via subcutaneous injection to subjects with ADPKD to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of RGLS8429. In Part B, a fixed-dose of RGLS8429 will be administered via subcutaneous injection to subjects with ADPKD to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of RGLS8429.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease
  • ADPKD
  • Polycystic Kidney, Autosomal Dominant
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female ADPKD patients, 18 to 70 years old
  2. Class 1C, 1D, or 1E Mayo Imaging Classification of ADPKD (based upon either the MRI obtained during screening, or a prior MRI obtained within 5 years of screening with documented Mayo classification)
  3. between 30 to 90 mL/min/1.73 m2
  4. (BMI) 18 to 35 kg/m2
  5. Must understand and consent to the study procedures explained in the ICF and be willing and able to comply with the protocol

Key Exclusion Criteria:

  1. Administration of tolvaptan in the 28 days before randomization
  2. Subject is mentally incapacitated or has significant emotional problems
  3. Any medical condition or social circumstance that, in the opinion of the Investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements; or may pose a risk to the subject's safety
  4. History or presence of alcoholism or drug abuse within the past 2 years prior to screening
  5. Only one kidney or kidney transplant recipient
  6. Participation in another clinical trial and/or exposure to any drug or approved therapy for investigational use within 28 days or 5 half-lives of the investigational drug's dosing, whichever is longer, prior to dosing. The 28-day or 5-half-life windows will be calculated from the date of the last dosing in the previous study to Day 1 of the current study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    RGLS8429

    The randomized,double blind part of the study (Part A) will consist of three sequential cohorts of approximately 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total). * Cohort 1: first dose level of RGLS8429 or placebo * Cohort 2: second dose level of RGLS8429 or placebo * Cohort 3: third dose level of RGLS8429 or placebo

    Drug: RGLS8429

  • Experimental
    Placebo

    The randomized double blind part of the study (Part A) will consist of three sequential cohorts of approximately 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total). * Cohort 1: first dose level of RGLS8429 or placebo * Cohort 2: second dose level of RGLS8429 or placebo * Cohort 3: third dose level of RGLS8429 or placebo

    Drug: Placebo

  • Experimental
    Open Label Fixed Dose RGLS8429

    The open-label fixed dose part of the study (Part B and Cohort 4) will consist of a single cohort of up to 30 subjects each receiving 300 mg RGLS8429.

    Drug: RGLS8429

Interventions

  • DrugRGLS8429

    Solution for subcutaneous injection

  • DrugPlacebo

    Solution for subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of RGLS4829: Incidence of AEs

    Incidence of adverse events over time

    Time frame: Baseline to Day 113

  2. Impact of RGLS8429 on ADPKD biomarkers

    Change from baseline in PC1, PC2, NGAL, and KIM-1 urine biomarkers

    Time frame: Baseline to Day 113

Secondary outcomes

  1. Impact of RGLS8429 on height-adjusted total kidney volume (htTKV)

    Change from baseline in htTKV

    Time frame: Baseline to Day 113

  2. Pharmacokinetic properties of RGLS8429: Cmax

    Maximum observed concentration (Cmax) of RGLS8429

    Time frame: Baseline to Day 113

  3. Pharmacokinetic properties of RGLS8429: Tmax

    Time to maximum observed concentration (Tmax) of RGLS8429

    Time frame: Baseline to Day 113

  4. Pharmacokinetic properties of RGLS8429: t½

    Half-life of RGLS8429 (t½)

    Time frame: Baseline to Day 113

07

Study locations

21 sites
  • Centricity Research Phoenix Multispecialty
    Mesa, Arizona 85206, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Yale Nephrology Outpatient Clinic
    New Haven, Connecticut 06510, United States
  • Mayo Clinic - Florida
    Jacksonville, Florida 32224, United States
  • Elixia
    Orlando, Florida 32806, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30904, United States
  • CARE Institute
    Boise, Idaho 83706, United States
  • CARE Institute
    Chubbuck, Idaho 83202, United States
  • The Idaho Kidney Institute
    Idaho Falls, Idaho 83404, United States
  • University of Chicago
    Chicago, Illinois 60617, United States
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center Jared Grantham Kidney Institute
    Kansas City, Kansas 66160, United States
  • Witchita Nephrology Group, PA
    Wichita, Kansas 67214, United States
  • University of Maryland School of Medicine, Nephrology
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • St. Clair Nephrology Research
    Roseville, Michigan 48066, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Swedish Center for Comprehensive Care
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jan 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 30, 2022
StartActual
Oct 6, 2022
Primary completionActual
Jan 27, 2025
CompletionActual
Mar 27, 2025
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05521191
Responsible party
Sponsor
First posted
Aug 30, 2022
Start date
Oct 6, 2022
Primary completion
Jan 27, 2025
Completion
Mar 27, 2025
Last update
Jun 3, 2025

Study contacts

Rekha Garg, MD
study director · Regulus Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion